Andecaliximab
Sponsors
Gilead Sciences, Ashibio Inc
Conditions
Breast CancerChronic Obstructive Pulmonary DiseaseColorectal CancerCrohn's DiseaseCystic FibrosisEsophagogastric CancerFibrodysplasia Ossificans ProgressivaGastric Adenocarcinoma
Phase 1
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors
CompletedNCT01803282
Start: 2013-03-29End: 2019-04-23Updated: 2020-06-02
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GS-5745 (Andecaliximab) in Adults With Moderate to Severe Active Ulcerative Colitis
CompletedNCT01831427
Start: 2013-03-28End: 2015-02-06Updated: 2021-02-01
Safety, Tolerability, and Pharmacokinetics of Andecaliximab in Adults With Chronic Obstructive Pulmonary Disease (COPD)
CompletedNCT02077465
Start: 2014-03-11End: 2014-10-27Updated: 2020-09-09
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma
TerminatedNCT02862535
Start: 2016-09-20End: 2019-10-25Updated: 2020-12-24
A Study of Andecaliximab in People With Spinal Cord Injury at Risk for Bone Growth Outside of the Normal Skeleton.
RecruitingNCT07024407
Start: 2025-05-14End: 2026-01-31Target: 10Updated: 2025-06-17
Phase 2
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
TerminatedNCT02405442
Start: 2015-04-30End: 2016-12-22Updated: 2019-04-23
Safety and Efficacy of Andecaliximab (GS-5745) in Adults With Moderately to Severely Active Ulcerative Colitis
TerminatedNCT02520284
Start: 2015-09-30End: 2016-11-30Updated: 2019-04-10
Effect of Andecaliximab on FEV1 in Adults With Cystic Fibrosis
TerminatedNCT02759562
Start: 2016-11-04End: 2017-07-21Updated: 2018-08-17
Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis
TerminatedNCT02862574
Start: 2016-12-15End: 2017-08-07Updated: 2018-06-27
Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma
CompletedNCT02864381
Start: 2016-09-01End: 2019-08-23Updated: 2020-09-18
A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)
Active, not recruitingNCT06508021
Start: 2024-10-25End: 2029-02-04Target: 92Updated: 2025-10-14
Phase 3
Related Papers
9 more papers not shown